1.Irritable Bowel Syndrome
The Korean Journal of Gastroenterology 2019;73(2):84-91
Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder. Its diagnosis is based on symptoms, and the Rome IV criteria are recognized as the gold diagnostic standard. The Korean Society of Neurogastroenterology and Motility (KSNM) recently updated their clinical practice guidelines for the treatment of IBS, which were last issued in 2011. In this updated edition, the KSNM defines IBS as a chronic, recurrent symptom complex that includes abdominal pain or discomfort, changes in bowel habits, and bloating for at least 6 months, which is somewhat broader than the previous definition. Four major topics have been changed in the up-dated version in-line with the results of recent studies, that is, colonoscopy; a diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols; probiotics; and rifaximin. Herein, we review the 2017 revised edition of the KSNM with respect to recommended clinical practice guidelines for IBS and compare these with other guidelines.
Abdominal Pain
;
Colonoscopy
;
Diagnosis
;
Diet
;
Disaccharides
;
Evidence-Based Practice
;
Gastrointestinal Diseases
;
Irritable Bowel Syndrome
;
Monosaccharides
;
Oligosaccharides
;
Probiotics
3.Helicobacter pylori and Hematologic Diseases
The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2020;20(1):11-20
Helicobacter pylori (H. pylori) is a Gram-negative spiral bacterium, classified as a group 1 carcinogen by the World Health Organization. H. pylori infection is a major cause of gastritis, gastric and duodenal ulcers, and gastric cancer. It is associated with the pathogenesis of several hematologic diseases. H. pylori eradication has been proven effective in gastric mucosa-associated lymphoid tissue lymphoma and primary immune thrombocytopenia. As H. pylori causes iron deficiency anemia via several mechanisms, some recent guidelines recommended its eradication from patients with iron deficiency anemia. There are discussions of other conditions that are not included in the international consensus and management guides on H. pylori, including monoclonal gammopathy, myelodysplastic syndrome, childhood leukemia, coagulation disorder, megaloblastic anemia, pernicious anemia, plasma cell dyscrasia, and Henoch-Schönlein purpura. Further studies are required to establish new strategies to improve the management of patients with an infection combined with a hematologic disease of controversial or peculiar association.
6.Low-grade Mucosa-associated Lymphoid Tissue Lymphoma of Stomach.
Sam Ryong JEE ; Sang Young SEOL
The Korean Journal of Gastroenterology 2005;45(5):312-320
Stomach is the most common site of primary extranodal lymphoma. Mucosa-associated lymphoid tissue (MALT) lymphoma is a unique type of extranodal lymphoma which is associated with Helicobacter pylori (H. pylori). The development of low-grade MALT lymphoma of stomach is dependent on H. pylori. A transformed clone carrying the translocation t(11;18)(q21;q21) forms a MALT lymphoma, the growth of which is independent of H. pylori and will not respond to bacterial eradication. And inactivation of the tumor suppressor genes, p53 can lead to high-grade transformation. Endoscopic ultrasound (EUS) is essential to document the extent of disease and is superior to CT scan in the detection of spread to perigastric lymph nodes and follow-up EUS may determine the response to therapy and detect the relapse in early phase. Lesions that are confined to the mucosa or submucosa of gastric wall can be successfully treated with H. pylori eradication. Those low-grade MALT lymphomas that are not H. pylori positive or do not respond to antibiotic therapy can be treated with surgery, radiation, or chemotherapy. Follow-up is critical in all patients who have been treated with H. pylori eradication and consists of multiple endoscopic biopsies and EUS.
Helicobacter Infections/complications
;
Helicobacter pylori
;
Humans
;
*Lymphoma, B-Cell, Marginal Zone/microbiology/pathology
;
Stomach Diseases/complications
;
*Stomach Neoplasms/microbiology/pathology
7.Effect of antispasmodic agents for the treatment of irritable bowel syndrome
Journal of the Korean Medical Association 2018;61(7):428-434
Antispasmodics are effective in reducing abdominal pain and controlling spasm. Irritable bowel syndrome (IBS) patients have characteristic key factors such as intestinal motility disorder and visceral hypersensitivity. So antispasmodics have been used in the treatment of IBS for decades. Mebeverine blocks intestinal peristalsis but are not significantly better than placebo. Alverine citrate combined with simethicone is effective treatment option in IBS. Otilonium and pinaverium bromide are poorly absorbed agents, so they have mostly local effect with minimal systemic adverse events. Phloroglucinol controls acute exacerbation of abdominal pain effectively. Tiropramide reduce abdominal discomfort without serious adverse events. Fenoverine control spasm in spastic colon but does not affect normal contraction. Trimebutine have dual actions that it inhibits hyperactive colon and activates hypomotile colon. Each drug has advantages and disadvantages. Antispasmodics are considered as the first treatment option of pain-dominant IBS.
Abdominal Pain
;
Citric Acid
;
Colon
;
Gastrointestinal Motility
;
Humans
;
Hypersensitivity
;
Irritable Bowel Syndrome
;
Muscle Spasticity
;
Parasympatholytics
;
Peristalsis
;
Phloroglucinol
;
Simethicone
;
Spasm
;
Trimebutine
8.Effect of antispasmodic agents for the treatment of irritable bowel syndrome
Journal of the Korean Medical Association 2018;61(7):428-434
Antispasmodics are effective in reducing abdominal pain and controlling spasm. Irritable bowel syndrome (IBS) patients have characteristic key factors such as intestinal motility disorder and visceral hypersensitivity. So antispasmodics have been used in the treatment of IBS for decades. Mebeverine blocks intestinal peristalsis but are not significantly better than placebo. Alverine citrate combined with simethicone is effective treatment option in IBS. Otilonium and pinaverium bromide are poorly absorbed agents, so they have mostly local effect with minimal systemic adverse events. Phloroglucinol controls acute exacerbation of abdominal pain effectively. Tiropramide reduce abdominal discomfort without serious adverse events. Fenoverine control spasm in spastic colon but does not affect normal contraction. Trimebutine have dual actions that it inhibits hyperactive colon and activates hypomotile colon. Each drug has advantages and disadvantages. Antispasmodics are considered as the first treatment option of pain-dominant IBS.
9.Retraction Notice to "Endoscopic Resection for Rectal Carcinoid Tumors: Comparision of Polypectomy and Endoscopic Submucosal Resection with Band Ligation".
Sang Heon LEE ; Seun Ja PARK ; Hyung Hun KIM ; Kyung Sun OK ; Ji Hyun KIM ; Sam Ryong JEE ; Sang Young SEOL ; Bo Mi KIM
Clinical Endoscopy 2015;48(1):87-87
This retracts the below mentioned article upon the authors' request.
10.Guidelines of Treatment for Peptic Ulcer Disease in Special Conditions.
Ji Hyun KIM ; Jeong Seop MOON ; Sam Ryong JEE ; Woon Geon SHIN ; Soo Heon PARK
The Korean Journal of Gastroenterology 2009;54(5):318-327
The pathogenesis, incidence, complication rates, response to acid suppression and Helicobacter pylori (H. pylori) eradication therapy in peptic ulcer associated with chronic disease such as liver cirrhosis, chronic renal failure, diabetes mellitus, and critically ill conditions are different from those with general population, so that the management strategies also should be differentiated. The eradication of H. pylori are not so effective for preventing recurrence of peptic ulcer in liver cirrhosis patients as shown in general population, and conservative managements such as preventing deterioration of hepatic function and decrease in portal pressure are mandatory to reduce the risk of ulcer recurrence. The standard triple therapy for H. pylori eradication are as effective in chronic renal failure patients as in normal population, but the frequency of side effects of amoxicillin is higher in the patients not receiving dialysis therapy. Delay in eradication therapy until beginning of dialysis therapy or modification of eradication regimen should be considered in such cases. High prevalence of asymptomatic peptic ulcers and increased mortality in complicated peptic ulcer disease warrant regular endoscopic surveillance in diabetic patients, especially with angiopathy. The prolongation of duration of eradication therapy also should be considered in diabetic patients with angiopathic complication because of lower eradication rate with standard triple regimens as compared to normal population. Prophylactic acid suppressive therapy is highly recommended in critically ill patients with multiple risk factors. Herein, we propose evidence-based treatment guidelines for the management of peptic ulcer disease in special conditions based on literature review and experts opinion.
Amoxicillin/therapeutic use
;
Anti-Bacterial Agents/therapeutic use
;
Critical Illness
;
Diabetes Mellitus/diagnosis/drug therapy
;
Helicobacter Infections/diagnosis/drug therapy
;
Helicobacter pylori
;
Humans
;
Kidney Failure, Chronic/diagnosis/therapy
;
Liver Cirrhosis/diagnosis/therapy
;
Peptic Ulcer/*therapy
;
Risk Factors